Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Abhishek A. et al, (2025), Efficacy and mechanism evaluation, 1 - 42
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2025), Efficacy and mechanism evaluation, 12, 47 - 48
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Abhishek A. et al, (2025), Efficacy and mechanism evaluation, 12, 43 - 44
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A. et al, (2024), Lancet rheumatol, 6, e92 - e104
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2023), Lancet rheumatology, 6, e92 - e104
How should we best measure participant-reported ‘average hand pain’: comparison of two methods from a randomized placebo-controlled feasibility study of post-menopausal women with hand osteoarthritis
Williams JA. et al, (2023), Osteoarthritis and cartilage, 31, s187 - s188
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.
Williams JAE. et al, (2022), Lancet rheumatol, 4, e725 - e737
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A. et al, (2022), Lancet respir med, 10, 840 - 850
Two-week interruption in methotrexate treatment versus treatment continued as usual and COVID-19 booster immunity in adults with inflammatory conditions (VROOM study): a randomised open label, superiority trial
Abhishek A. et al, (2022), The lancet respiratory medicine
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
Abhishek A. et al, (2022), Bmj open, 12
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS. et al, (2016), Lancet oncol, 17, 1543 - 1557
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D. et al, (2015), Gut, 64, 111 - 120
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Dutton SJ. et al, (2014), Lancet oncol, 15, 894 - 904
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D. et al, (2014), J clin oncol, 32, 1031 - 1039
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S. et al, (2013), Journal of clinical oncology, 31, TPS5615 - TPS5615
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S. et al, (2013), Journal of clinical oncology, 31
Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG).
Dutton SJ. et al, (2013), Journal of clinical oncology, 31, 6 - 6